Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Study to Determine Efficacy and Safety of IFX-1 in Subjects With Moderate to Severe Hidradenitis Suppurativa

NCT03487276 is registered in ClinicalTrials.gov with InflaRx GmbH as lead sponsor.

NCT NCT03487276
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03487276 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Study to Determine Efficacy and Safety of IFX-1 in Subjects With Moderate to Severe Hidradenitis Suppurativa
Lead sponsor
InflaRx GmbH
Phase
Phase 2
Overall status
Completed
Start date
February 26, 2018
Completion date
January 27, 2020
Enrollment
179 (actual)
Sites
41

Conditions

As the registry lists them; a condition with its own page is linked.

hidradenitis suppurativa (hs)